secwatch.observer — SEC 8-K summary
======================================

Issuer:     Raphael Pharmaceutical Inc. (RAPH)
CIK:        0001415397
Form:       8-K/A
Filed at:   2023-01-26T23:59:59+00:00
Accession:  0001213900-23-005219
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Raphael Pharma corrects CTO deal: $9k/month, 999k warrants at $0.01, royalty share
--------------------------------------------------------------------------------

- Service agreement with CTO Dr. Igal Louria Hayon corrected, monthly fee $9,000 through Dec 31, 2022.
- Issuance of 999,000 warrants at $0.01 per share, expiring July 5, 2024.
- Additional 350,000 warrants at $0.01 if company initiates cannabis clinical trial or new cannabis research.
- Royalty payments: 15% of net royalties from medical cannabis CBD oil for COVID-19 and for rheumatoid arthritis.
- Term through Dec 31, 2023; termination requires 120 days notice and fee equal to remaining monthly fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1415397/000121390023005219/0001213900-23-005219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1415397/000121390023005219/ea172085-8ka1_raphael.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-005219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer